尿路上皮肿瘤患者应用吉西他滨和奥沙利铂治疗的临床效果

Clinical effect of gemcitabine combined with oxaliplatin in the treatment of urothelial tumors

目的探讨吉西他滨联合奥沙利铂治疗尿路上皮肿瘤的临床效果。方法选取我科收治的52例尿路上皮肿瘤患者为研究对象,按治疗方案不同分为对照组(n=26)与观察组(n=26)。对照组患者单纯采用吉西他滨治疗,观察组患者采用吉西他滨+奥沙利铂治疗。比较两组患者的临床效果及药物不良反应发生情况。结果观察组患者治疗总有效率为66.67%,临床控制率为87.50%;对照组治疗总有效率为43.48%,临床控制率为73.91%,观察组患者总有效率及临床控制率明显高于对照组(P<0.05);观察组药物不良反应总发生率为25.00%,明显低于对照组的47.83%,差异有统计学意义(P<0.05)。结论与单纯采用吉西他滨相比,吉西他滨联合奥沙利铂治疗尿路上皮肿瘤临床效果更显著,安全性更高,值得在临床中推广使用。

Objective To investigate the effect of gemcitabine combined with oxaliplatin in the treatment of urothelial tumors. Methods Fifty-two urothelial tumors patients were selected and divided into control group（n=26） and observation group（n=26） according to different treatment methods. The control group was given gemcitabine alone, and the observation group was treated with gemcitabine combined with oxaliplatin. The clinical efficacy and adverse reactions incidence rate of the two groups were compared. Results The total effective rate and clinical control rate of the observation group were 66.67% and 87.50% respectively, which were significantly higher than 43.48% and 73.91% of the control group（P〈0.05）. The total incidence rate of adverse reaction of the observation group was 25.00%, which was lower than 47.83% of the control group（P〈0.05）. Conclusion Compared with gemcitabine alone, gemcitabine combined with oxaliplatin in the treatment of urothelial tumors has more significant efficacy and higher safety, which is worthy of clinical application and promotion.